AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...

Discover Daiichi Sankyo's groundbreaking patent for monoclonal antibodies targeting LAG-3, offering new hope for treating autoimmune diseases with enhanced efficacy.

Daiichi Sankyo and AstraZeneca saw a dip in stock prices after announcing that their Phase III TROPION-Breast01 trial for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Japan stocks were higher after the close on Tuesday, as gains in the Insurance, Textile and Paper & Pulp sectors led shares ...

Japan equities were higher at the close on Tuesday, as gains in the Insurance, Textile and Paper & Pulp sectors led shares ...

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...

EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...

IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...